Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive 19F-magnetic resonance spectroscopy

Journal of Clinical Oncology

Volumn 18, Issue 2, 2000, Pages 255-261

  Presant, Cary A ^a   Wolf, Walter ^a   Waluch, Victor ^a   Wiseman, Charles L ^a   Weitz, Ilene ^a   Shani, Jashovam ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESEARCH; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; HUMAN; IN VIVO STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; STOMACH CANCER;

EID: 0033972305     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.2.255     Document Type: Article

References (21)

1. Pinedo HM, Peters GJ; Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6:1653-1664, 1988
2. Wolf W, Presant CA, Servis KL, et al: Tumor trapping of 5-FU: In vivo 19F-NMRS pharmacokinetics in tumor-bearing humans and rabbits. Proc Natl Acad Sci USA 87:492-496, 1990
3. Presant CA, Wolf W, Albright MJ, et al: Human tumor 5-FU trapping: Clinical correlations of in vivo 19F -NMRS pharmacokinetics. J Clin Oncol 8:1868-1873, 1990
4. Presant CA, Wolf W, Waluch V, et al: Association of intratumoral pharmacokinetics of 5-FU with clinical response. Lancet 343: 1184-1187, 1994
5. Rustum YM, Cao S, Zhang Z: Rationale for treatment design: Biochemical modulation of 5-fluorouracil by leucovorin. Cancer J Sci Am 4:12-18, 1998
6. Labianca R, Pessi A, Facendola G, et al: Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: A critical review of comparative studies. Eur J Cancer 32A:S7-12, 1996 (suppl 5)
7. Ardalan B, Luis R, Jaime M, et al: Biomodulation of fluorouracil in colorectal cancer. Cancer Invest 16:237-251, 1998
8. Horowitz R, Schwartz EL, Wadler S: Modulation of 5-fluorouracil by interferon: A review of potential cellular targets. Med Oncol 12:3-8, 1995
9. Houghton JA, Morton CL, Adkins DA, et al: Locus of interaction among 5-FU leucovorin and interferon-α2a in colon carcinoma cells. Cancer Res 53:4243-4250, 1993
10. Lee M, Price D, Specht S, et al: Interferon modulation of 5-FU: Use in neoadjuvant therapy inhibits experimenlal liver metastases in nude mice. Anticancer Drugs 3:413-418, 1992
11. Fornasiero A, Daniele O, Giotto C, et al: Interferon-α2 and 5-FU in advanced colorectal cancer. Tumori 76:385-388, 1990
12. Schwartz LE, Baptiste N, O'Connor CJ, et al: Potentiation of the anti-tumor activity of 5-FU in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylation. Cancer Res 54:1472-1478. 1994
13. Kocha W: 5-FU plus interferon-α2a versus 5-FU plus leucovorin in metastatic colorectal cancer: Results of a multicenter multinational phase III study. Proc Am Soc Clin Oncol 12:193, 1993 (abstr 562)
14. York M, Greco FA, Figlin RA, et al: A randomized phase III trial comparing 5-FU with or without interferon-α2a for advanced colorectal cancer. Proc Am Soc Clin Oncol 12:200, 1993 (abstr 590)
15. Machov D: The pharmacological modulation of 5-FU with folinic acid methotrexate trimetrexate and m-phosphonacetyl-1-aspartic acid (PALA) mechanisms of the interactions and clinical data. Bull Cancer 9:74s-78s, 1994 (suppl 2)
16. Cadman E, Heimer R, Davis L: Enhanced 5-FU nucleotide formation after MTX administration: Explanation for drug synergism. Science 205:1135-1137, 1979
17. Marsh JC, Bertino JR, Katz KH, et al: The influence of drug interval on the effect of MTX and 5-FU in the treatment of advanced colorectal cancer. J Clin Oncol 9:371-380, 1991
18. 19F-NMRS. Cancer Res 51:5806-5812, 1991
19. 19F-MRS. Cancer Invest 18:20-27, 2000
20. Rosenfeld D, Zur Y: Design of adiabatic selective pulses using optimal control theory. Magn Reson Med 36:401-409, 1996
21. Green S, Weiss GR: Southwest Oncology Group standard response criteria endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992